Lymphoma  >>  abexinostat (CG-781) 
Welcome,         Profile    Billing    Logout  

8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
abexinostat (CG-781) / Xynomic
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
96
RoW
Abexinostat
Xynomic Pharmaceuticals, Inc.
Lymphoma, Follicular
02/24
09/24
FORERUNNER, NCT03600441 / 2018-001701-82: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting
2
139
Europe, US
Abexinostat
Xynomic Pharmaceuticals, Inc.
Follicular Lymphoma
12/24
12/25
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
170
RoW
abexinostat
Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
12/24
05/25
2009-013691-47: Phase I/II dose-escalation study of S 78454 in Lymphoma

Ongoing
1/2
80
Europe
S78454, S78454,
Institut de Recherches Internationales Servier, Pharmacyclics LLC, Pharmacyclics. LLC, Pharmacyclics. Inc, , Pharmacyclics LLC, ADIR
Hodgkin\'s disease (HD) , non-Hodgkin lymphoma (NHL) and chronic lymphocytic Leukaemia (CLL)
 
 
NCT02587299: Study of Histone Deacetylase Inhibitor (HDACi) Abexinostat, Combined With Ibrutinib, in Subjects With R/R Lymphomas

Not yet recruiting
1/2
140
US
Abexinostat, Ibrutinib
Pharmacyclics
Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma
12/18
 
NCT02610998: Study of Histone Deacetylase Inhibitor (HDACi) Abexinostat, Combined With Ibrutinib, in Subjects With Relapsed/Refractory (R/R) Lymphomas

Not yet recruiting
1/2
140
US
Abexinostat, Ibrutinib
Pharmacyclics
Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma
06/20
 
NCT04024696: A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Active, not recruiting
1/2
12
RoW
Abexinostat
Xynomic Pharmaceuticals, Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Hodgkin Lymphoma
02/24
06/24
NCT03939182: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Active, not recruiting
1
15
US
Abexinostat, Ibrutinib
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC, Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
05/25
05/25

Download Options